Revolution Medicines (RVMD) Expected to Announce Quarterly Earnings on Wednesday

Revolution Medicines (NASDAQ:RVMD) is anticipated to post its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of ($2.35) per share and revenue of $25.58 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Revolution Medicines (NASDAQ:RVMD) last issued its earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same period in the previous year, the company posted ($1.31) EPS. On average, analysts expect Revolution Medicines to post ($8.94) EPS for the current fiscal year and ($6.29) EPS for the next fiscal year.

Revolution Medicines Trading Up 1.3%

Shares of NASDAQ RVMD opened at $186.22 on Wednesday. The firm’s 50 day moving average price is $200.66 and its 200-day moving average price is $154.67. Revolution Medicines has a 52-week low of $56.66 and a 52-week high of $224.31.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on RVMD shares. Morgan Stanley initiated coverage on shares of Revolution Medicines in a research report on Thursday, September 10th. They set an “overweight” rating and a $255.00 price target for the company. Sanford C. Bernstein upped their price objective on Revolution Medicines from $151.00 to $179.00 and gave the company a “market perform” rating in a research report on Friday, August 21st. TD Cowen reaffirmed a “buy” rating and issued a $250.00 price objective on shares of Revolution Medicines in a research report on Wednesday, October 21st. Stifel Nicolaus increased their target price on Revolution Medicines from $215.00 to $230.00 and gave the company a “buy” rating in a research note on Wednesday, September 9th. Finally, Mizuho lifted their target price on Revolution Medicines from $185.00 to $215.00 and gave the stock an “outperform” rating in a report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Revolution Medicines currently has an average rating of “Moderate Buy” and an average price target of $242.90.

Insider Activity

In related news, COO Margaret A. Horn sold 4,967 shares of the stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $199.24, for a total transaction of $989,625.08. Following the transaction, the chief operating officer owned 149,680 shares in the company, valued at $29,822,243.20. This represents a 3.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mark A. Goldsmith sold 13,988 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $199.24, for a total transaction of $2,786,969.12. Following the completion of the sale, the insider owned 253,342 shares in the company, valued at $50,475,860.08. This represents a 5.23% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 290,991 shares of company stock worth $59,422,765. 7.60% of the stock is owned by corporate insiders.

About Revolution Medicines

Revolution Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with RAS-mutant cancers. The company’s research platform is designed to discover and develop medicines that inhibit RAS proteins, which play a central role in the growth and spread of many cancers and have historically been difficult to target.

Its investigational pipeline includes RAS(ON) inhibitors and other precision oncology candidates, including daraxonrasib (RMC-6236), a pan-RAS inhibitor being evaluated in multiple solid tumors, as well as programs directed at specific mutations such as KRAS G12C and KRAS G12D.